KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Palvella Therapeutics (PVLA) Enterprise Value (2016 - 2026)

Palvella Therapeutics has reported Enterprise Value over the past 10 years, most recently at -$59.2 million for Q4 2022.

  • Quarterly Enterprise Value rose 49.76% to -$59.2 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$59.2 million through Dec 2022, up 49.76% year-over-year, with the annual reading at -$59.2 million for FY2022, 49.76% up from the prior year.
  • Enterprise Value was -$59.2 million for Q4 2022 at Palvella Therapeutics, up from -$91.2 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$59.2 million in Q4 2022 and troughed at -$159.6 million in Q1 2018.
  • The 5-year median for Enterprise Value is -$95.7 million (2019), against an average of -$101.2 million.
  • Year-over-year, Enterprise Value tumbled 200.01% in 2018 and then soared 49.76% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$125.2 million in 2018, then increased by 16.8% to -$104.2 million in 2019, then soared by 32.37% to -$70.4 million in 2020, then crashed by 67.19% to -$117.8 million in 2021, then skyrocketed by 49.76% to -$59.2 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Enterprise Value are -$59.2 million (Q4 2022), -$91.2 million (Q3 2022), and -$80.9 million (Q2 2022).